Immunic, Inc. (IMUX)
Chart Events
Performance Outlook
| Previous Close | 13.31 |
| Open | 13.20 |
| Bid | 12.50 x 2900 |
| Ask | 13.26 x 1300 |
| Day's Range | 12.81 - 13.43 |
| 52 Week Range | 11.50 - 28.21 |
| Volume | 319,109 |
| Avg. Volume | 127,985 |
| Market Cap | 282.742M |
| Beta (5Y Monthly) | 1.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.84 |
| Earnings Date | Aug 02, 2021 - Aug 06, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 57.50 |
Fair Value
Related Research
- PR Newswire
Immunic, Inc. to Participate in Industry and Investor Conferences in June
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in June:
- PR Newswire
Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the appointment of Inderpal Singh as General Counsel, effective today. In his new role, Mr. Singh will be responsible for legal and compliance matters and will become part of the management team of Immunic.
- Simply Wall St.
Duane Nash Is The Executive Chairman of Immunic, Inc. (NASDAQ:IMUX) And They Just Picked Up 40% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the Immunic, Inc. ( NASDAQ:IMUX ) Executive...
